MELVILLE, NY -- (MARKET WIRE) -- October 11, 2006 -- Population Diagnostics, Inc. (PDI) announced that it has agreed to terms with Empire Genomics LLC (EG) to establish an infrastructure for PDI to begin commercializing at full scale its core technology platform. The core technology of PDI will facilitate the company’s primary objective, which is to develop novel predictive tests for the molecular diagnostic and personalized medicine markets. The understanding between PDI and EG is multifaceted, where EG intends to purchase access to the core technology platform of PDI to support its internal and collaborative projects, and service/supply relationships with 3rd parties. PDI intends to use genetic information derived from EG’s high quality microarray products and services to build its core technology platform as well as its DNA biomarker discovery program. PDI and EG also intend to co-market and co-promote the products and services of their respective companies.
